Stocks of Esperion Therapeutics Inc (NASDAQ:ESPR) traded higher last session on Wall Street, up 5.58% to $2.46.
ESPR stock price is now 2.76% away from the 50-day moving average and 9.85% away from the 200-day moving average. The market capitalization of the company currently stands at $484.70M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $8, Cantor Fitzgerald recently initiated with Overweight rating for Esperion Therapeutics Inc (NASDAQ: ESPR). On June 20, 2024, BofA Securities Downgraded its previous ‘Neutral’ rating to ‘Underperform’ on the stock keeping its target price maintained at $2.50, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Warren Eric, Officer bought 2,234 shares of the company’s stock on Dec 17 ’24. The stock was bought for $5,426 at an average price of $2.43. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 17 ’24, Officer Koenig Sheldon L. bought 12,447 shares of the business’s stock. A total of $30,698 was incurred on buying the stock at an average price of $2.47. A total of 1.00% of the company’s stock is owned by insiders.
During the past 12 months, Esperion Therapeutics Inc has had a low of $1.58 and a high of $3.94. The fifty day moving average price for ESPR is $2.3856 and a two-hundred day moving average price translates $2.23925 for the stock.
The latest earnings results from Esperion Therapeutics Inc (NASDAQ: ESPR) was released for 2024-09-30. The company reported revenue of $51.63 million for the quarter, compared to $33.97 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 52.0 percent.
